STOCK TITAN

Pluri Inc - PLUR STOCK NEWS

Welcome to our dedicated page for Pluri news (Ticker: PLUR), a resource for investors and traders seeking the latest updates and insights on Pluri stock.

Overview of Pluri Inc

Pluri Inc is a pioneering biotechnology company that transforms cells into scalable, commercial products designed to promote global well-being and sustainability. At its core, Pluri Inc harnesses a patented and validated three-dimensional (3D) cell expansion system to address challenges across regenerative medicine, food technology, and agricultural technology. By leveraging cell expansion techniques in a GMP-compliant manufacturing environment, the company establishes a revolutionary model that is both consistent and cost effective.

Innovative Technology Platform

Pluri Inc's technological prowess stems from its state-of-the-art 3D cell expansion platform. This proprietary system enables the mass production of high-quality cell-based products with exceptional batch-to-batch consistency, ensuring that the therapeutic and functional attributes of each product remain intact. The platform underpins several business segments including regenerative therapies, immunotherapies, and even cell-based solutions for food and agriculture industries. By employing robust bioreactor systems and automated processes, Pluri sets a new standard for cell manufacturing at an industrial scale.

Applications in Regenerative Medicine and Immunotherapy

One of the principal applications of Pluri Inc’s technology is in the field of regenerative medicine. The company develops cell therapies that do not require tissue or genetic matching, enabling off-the-shelf solutions for diverse medical conditions. Pluri’s approach involves the use of specialized cell types, such as placental-derived cells, which release vital biomolecules—cytokines, chemokines, and growth factors—that stimulate the body’s own repair mechanisms. This innovative strategy has been applied in developing treatments for inflammation, ischemia, hematological disorders, and radiation exposure. Moreover, Pluri has expanded its research into immunotherapy, unveiling a placental allogeneic MAIT cell platform designed to treat solid tumors. The technology leverages the unique properties of MAIT cells, which are capable of targeting tumor sites effectively with high specificity and minimal risk of complications such as Graft versus Host Disease.

Diversification into FoodTech and AgTech

Beyond traditional medical applications, Pluri Inc is redefining the landscape of food technology and agricultural innovation. The company has strategically partnered with industry peers to translate its cell expansion expertise into the development of cultivated food products. Through collaborations, Pluri’s technology is used to replicate essential biological components found in human and animal milk, which serve as critical ingredients in the formulation of advanced medical foods. Furthermore, its subsidiary endeavors, such as Ever After Foods, harness the 3D expansion platform to produce cultivated meat. This cultivated meat technology offers a sustainable alternative to conventional meat production, promising significant reductions in production costs and environmental impact.

Contract Development and Manufacturing Organization (CDMO) Services

In addition to its internal product development, Pluri Inc has established itself as a reliable partner in outsourced manufacturing. Through its CDMO division, Pluri provides full-scale manufacturing services for innovative cell-based therapies. The highly regulated, GMP-grade facilities ensure that both early-stage clinical products and commercial-scale batches are produced with absolute precision. This service division supports collaborations with notable biotechnology companies, optimizing their product development pipelines and bringing therapeutic products to the market efficiently.

Strategic Collaborations and Market Position

Pluri Inc’s strategic collaborations are a cornerstone of its business model. The company frequently partners with global institutions, leading research centers, and industry pioneers to capitalize on its technology platform. Recent joint projects have addressed unmet medical needs in immunotherapy—a collaboration featuring renowned oncology researchers has fortified its MAIT cell platform—and advanced cultivated meat production with industry leaders in food manufacturing. By forming these alliances, Pluri not only diversifies its revenue stream but also reinforces its market position as a multidimensional biotech innovator. The company is uniquely positioned to serve a broad spectrum of industries ranging from therapeutic solutions to sustainable food production.

Operational Excellence and Regulatory Compliance

Central to the success of Pluri Inc is its unwavering commitment to operational excellence and adherence to regulatory standards. The company’s manufacturing facilities meet stringent criteria set by regulatory agencies worldwide, including the FDA, EMA, and PMDA. This rigorous compliance framework enables Pluri to maintain high quality and consistency in its products, further bolstering investor and industry confidence in its offerings. The advanced manufacturing process is not only scalable but also designed to be adaptable, ensuring that it can meet the evolving demands of both clinical and commercial markets.

Industry Keywords and Fundamentals

From the outset, Pluri Inc integrates key industry terminology such as cell expansion, regenerative medicine, and GMP manufacturing into its narrative. These buzzwords are not merely cosmetic; they represent the underlying principles that drive the company’s innovation. By focusing on robust technological infrastructure, strategic partnerships, and multi-dimensional applications, Pluri Inc embodies the future of biotechnology in a manner that is both comprehensive and sustainable.

Comprehensive Business Model

The business model of Pluri Inc is both integrated and diversified. It encapsulates the direct development of cell-based products along with CDMO services, thereby addressing the needs of multiple market segments. Its revenue streams are based on diverse channels including technology licensing, strategic collaborations, contract manufacturing, and direct product sales. The company’s ability to seamlessly integrate advanced science with high-volume production capabilities is what sets it apart in a competitive market environment. The comprehensive nature of its platform facilitates rapid commercialization without sacrificing precision or consistency.

Investor and Market Considerations

For investors and market researchers, understanding Pluri Inc involves appreciating the depth of its innovation and the breadth of its applications. The company’s operations are rooted in decades of research and a continuous drive towards technological advancement. Through its multi-disciplinary approach, Pluri Inc addresses current market challenges across healthcare, food production, and sustainable agriculture. Its unbiased focus on science, quality, and regulatory compliance makes it a reliable subject of study for stakeholders seeking to understand next-generation biotechnological solutions.

Conclusion

In summary, Pluri Inc stands at the crossroads of modern biotechnology, leveraging cutting-edge 3D cell expansion technology to create solutions that span regenerative medicine, immunotherapy, food technology, and agricultural innovation. Its multifaceted approach, combined with strong industry connections and strict regulatory compliance, positions the company as an essential study subject for those exploring the future of scalable, cell-based products. With a focus on consistency, sustainability, and scientific excellence, Pluri Inc continues to redefine the parameters of what is possible in the biotechnology sector.

  • Core Strengths: Innovative 3D cell expansion, GMP-grade manufacturing, and versatile applications in multiple industries.
  • Strategic Focus: Regenerative medicine, immunotherapy for solid tumors, cultivated meat production, and advanced medical foods.
  • Collaborative Edge: Strategic partnerships with leading research institutions and global industry players.
  • Market Impact: Transforming therapeutic development and sustainable production methods to meet global challenges.
Rhea-AI Summary

Pluri Inc. (Nasdaq:PLUR) (TASE:PLUR) has signed a tech transfer and manufacturing agreement with Kadimastem (TASE: KDST) through its PluriCDMO™ division. PluriCDMO™ will manufacture two cell therapy product candidates for Kadimastem: AstroRx® for ALS treatment and IsletRx for diabetes treatment. This collaboration leverages Pluri's 47,000 square foot GMP cell production facility and expertise in developing and manufacturing cell-based products. The agreement supports Kadimastem's preparation for clinical trials and expansion into the U.S. market, particularly for an upcoming FDA Phase 2a study of AstroRx®. This partnership highlights PluriCDMO™'s versatility and commitment to advancing innovative life-saving therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.14%
Tags
none
-
Rhea-AI Summary

Pluri has entered a €1 million proof of concept (POC) agreement with an international agriculture The collaboration aims to boost global vegetable supply, shorten supply chains, and promote sustainable agriculture. Pluri’s 3D cell expansion technology and the partner's market expertise will work together to minimize environmental impact and enhance food security. This initiative aligns with Pluri's strategy to partner with global companies and generate revenue through innovative projects. The global vegetable farming market, valued at $1.3 trillion, is projected to grow to $1.6 trillion by 2029, driven by a rising global population.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.99%
Tags
none
-
Rhea-AI Summary

Pluri's subsidiary, Ever After Foods, has secured $10 million in strategic investments from U.S. and EU investors, including Tnuva Group. This funding aims to tackle scalability challenges in cultivated food production. Ever After Foods' innovative platform can produce cultivated meat, fish, and seafood with significant cost-efficiency, reducing production costs by over 90% and increasing protein and lipid yields substantially.

Leveraging Pluri's technology, Ever After Foods aims to expand its global market presence. The technology enables natural production of muscle and fat tissues, ensuring taste and texture akin to conventional meat. The new funding will also broaden Ever After Foods' scope to include cultivated fish, reinforcing its position as a leading technology enabler in the food industry.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.67%
Tags
none
Rhea-AI Summary

Pluri announced that the U.S. National Institute of Allergy and Infectious Diseases (NIAID) has exercised a $1.4 million second-year funding option for a contract to develop PLX-R18, a cell therapy for Acute Radiation Syndrome (H-ARS). The contract, part of a $4.2 million three-year agreement, supports manufacturing, in vitro, and in vivo studies for PLX-R18. The therapy aims to counteract hematopoietic complications from ionizing radiation. Significant survival rate increases in both animal and human studies have been reported. PLX-R18 has also received FDA Orphan Drug Designation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.75%
Tags
none
-
Rhea-AI Summary

Pluri (Nasdaq: PLUR) has announced a strategic partnership with Wilk Technologies to create a medical food product derived from human breast milk for the elderly. This innovative product utilizes Pluri's 3D cell-expansion technology in combination with Wilk's cell-cultured milk components. The global elderly nutrition market, valued at $25.2 billion, is projected to reach $39.7 billion within the next decade. This collaboration aims to meet the unique nutritional needs of seniors, enhancing their quality of life while addressing age-related health concerns and chronic illnesses.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.82%
Tags
none
-
Rhea-AI Summary

Pluri Inc. launched a novel immunotherapy platform for solid tumor cancer treatment utilizing placental MAIT cells, a unique type of immune cells with great potential. Pluri's proprietary technology overcomes challenges in expanding MAIT cells, offering advantages over conventional T cells. The global cancer immunotherapy market is projected to reach $275.11 billion by 2032. Renowned cancer researchers Dr. Prasad S. Adusumilli and Dr. Richard L. Kendall joined Pluri's Scientific Advisory Board to support this groundbreaking platform.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.03%
Tags
none
Rhea-AI Summary
Pluri Inc. unveils a groundbreaking method for expanding immune cells using proprietary technology, securing a new U.S. patent. The innovative 3D cell expansion technology mimics the natural lymph node environment, ensuring the integrity and functionality of immune cells. This advancement positions Pluri at the forefront of allogeneic cell therapy, promising significant therapeutic advancements and commercial success. The estimated total addressable market for immune cell engineering is projected to grow to $11.66 billion by 2030.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2%
Tags
none
-
Rhea-AI Summary
Pluri Inc. announces participation in various conferences to showcase its innovative cell-based solutions and business verticals. The company's leadership will present at MIW, ATiO Conference 2024, Biomed Israel, and Bio International Convention, highlighting advancements in 3D cell expansion technology, cell-based coffee business, and PLX-PAD therapy product.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.95%
Tags
conferences
-
Rhea-AI Summary
Pluri Inc. announces a reverse share split of its common shares at a ratio of 1-for-8, reducing outstanding shares from 41,816,959 to approximately 5,227,120. The split will not impact ownership or voting power, with fractional shares rounded up. Equiniti Trust Company, will act as the exchange agent for the reverse split.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.73%
Tags
Rhea-AI Summary
Pluri Inc. addresses price instability in the coffee industry highlighted in the International Coffee Organization's 2024 Market Report by introducing cell-based coffee production, offering a sustainable and innovative solution.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.08%
Tags
none

FAQ

What is the current stock price of Pluri (PLUR)?

The current stock price of Pluri (PLUR) is $4.3 as of April 1, 2025.

What is the market cap of Pluri (PLUR)?

The market cap of Pluri (PLUR) is approximately 30.1M.

What is the primary focus of Pluri Inc?

Pluri Inc is focused on creating scalable, cell-based products using its patented 3D cell expansion platform. Its applications span regenerative medicine, immunotherapy, foodtech, and agtech.

How does Pluri Inc generate its revenue?

The company generates revenue through multiple channels including technology licensing, direct sales of cell-based products, contract manufacturing services, and strategic partnerships with leading industry players.

What sets Pluri Inc's technology platform apart?

Pluri Inc's technology platform is distinguished by its patented 3D cell expansion capability, which allows for industrial-scale, consistent, and cost-effective cell production in a GMP-compliant setting.

In which industries does Pluri Inc operate?

Pluri Inc operates across several industries including regenerative medicine, immunotherapy for solid tumors, food technology for developing medical foods, and agricultural technology through cultivated meat production.

What are some of the strategic collaborations of Pluri Inc?

Pluri Inc has formed strategic partnerships with companies in immunotherapy, cellular agriculture, and clinical manufacturing. These collaborations help advance its platforms across therapeutic and food production segments.

How does Pluri Inc ensure product quality?

The company operates GMP-compliant facilities with strict regulatory oversight from agencies like the FDA and EMA. This ensures that every batch of its cell-based products maintains high quality and consistency.

What role does Pluri Inc play in the foodtech and agtech sectors?

Pluri Inc leverages its advanced cell expansion technology to develop cultivated meat and innovative medical foods. Its work in these sectors is designed to address sustainability and food security challenges.

What is the significance of Pluri Inc’s CDMO services?

The CDMO division of Pluri Inc provides comprehensive contract development and manufacturing services for cell-based therapies. This supports other biotechnology companies in scaling their products from clinical trials to commercial production.
Pluri Inc

Nasdaq:PLUR

PLUR Rankings

PLUR Stock Data

30.09M
4.02M
42.57%
10.38%
0.37%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
Israel
HAIFA